Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali Therapeutics's ROE % for the quarter that ended in Jun. 2026 was -57.32%. Denali Therapeutics's PB Ratio for the quarter that ended in Jun. 2026 was 0.73.
Denali Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -78.52%.
Denali Therapeutics ROE % Adjusted to Book Value Related Terms
Denali Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Denali Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics ROE % Adjusted to Book Value Chart
BSP:D2NL34 vs RCUS, ALMS, ELVN: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Denali Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -78.52% mean?
Denali Therapeutics (BSP:D2NL34) has a ROE % Adjusted to Book Value of -78.52% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Denali Therapeutics and its competitors.
Is Denali Therapeutics' ROE % Adjusted to Book Value too high?
Denali Therapeutics' current ROE % Adjusted to Book Value is -78.52%. Overall, Denali Therapeutics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' ROE % Adjusted to Book Value compare to RCUS and ALMS?
Denali Therapeutics' ROE % Adjusted to Book Value of -78.52% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Denali Therapeutics and its competitors. Denali Therapeutics's current ROE % Adjusted to Book Value is -78.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (BSP:D2NL34) has a current ROE % Adjusted to Book Value of -78.52%. The current ROE % Adjusted to Book Value is -78.52%. Denali Therapeutics' overall GF Score™ is 6/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Denali Therapeutics (BSP:D2NL34), the current ROE % Adjusted to Book Value is -78.52% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
6GF Score
Get the complete analysis for BSP:D2NL34
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:D2NL34 has been successfully added to your 
